Spotlight on Internal Medicine
Reinforcing the Roles of Biologic Therapy and Interprofessional Care in Improving Patient Outcomes in Severe and Difficult-to-Control Asthma
StartActivity Details
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: July 24, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.
Learning Objectives
- Differentiate between phenotypes in patients with asthma according to pathogenic mechanisms and biomarkers
- Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
- Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma
Activity Description
Asthma is a heterogeneous disease involving multiple inflammatory pathways. While many patients can be successfully treated, others suffer from severe or difficult-to-control disease, compounded by multiple atopic conditions, and a poor quality of life. In this interprofessional panel, experts will discuss the different phenotypes and endotypes of asthma, how they affect therapy, the role of biologics in the treatment of severe or uncontrolled asthma, impact comorbid atopy can have on management and quality of life, and how we can work together as a healthcare team to manage severe and difficult-to-treat asthma.
Faculty
Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO
Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH
Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.
David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).
Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
Planners and managers have no relevant financial relationship(s) with
ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Interprofessional Continuing Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 80% or higher on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Activity Details
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: July 24, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.
Learning Objectives
- Differentiate between phenotypes in patients with asthma according to pathogenic mechanisms and biomarkers
- Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
- Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma
Activity Description
Asthma is a heterogeneous disease involving multiple inflammatory pathways. While many patients can be successfully treated, others suffer from severe or difficult-to-control disease, compounded by multiple atopic conditions, and a poor quality of life. In this interprofessional panel, experts will discuss the different phenotypes and endotypes of asthma, how they affect therapy, the role of biologics in the treatment of severe or uncontrolled asthma, impact comorbid atopy can have on management and quality of life, and how we can work together as a healthcare team to manage severe and difficult-to-treat asthma.
Faculty
Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO
Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH
Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.
David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).
Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
Planners and managers have no relevant financial relationship(s) with
ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Interprofessional Continuing Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 80% or higher on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Internal Medicine Presentations
Case Conundrums in COVID-19: A Patient Presenting to the ED With Mild COVID-19
StartActivity Details
Expires: March 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
- Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.
Activity Description
In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.
Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Phyllis C. Tien, MD
Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA
Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: March 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
- Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.
Activity Description
In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.
Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Phyllis C. Tien, MD
Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA
Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Case Conundrums in COVID-19: A Newly Admitted Patient With COVID-19 and Worsening Respiratory Symptoms
StartExpires: March 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
- Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.
Activity Description
In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.
Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Phyllis C. Tien, MD
Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA
Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Expires: March 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
- Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.
Activity Description
In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.
Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Phyllis C. Tien, MD
Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA
Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Case Conundrums in COVID-19: A Patient With COVID-19 Experiencing Hyperinflammation
StartExpires: March 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
- Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.
Activity Description
In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.
Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Randy Q. Cron, MD, PhD
Professor of Pediatrics
Arthritis Foundation, Alabama Chapter Endowed Chair in Pediatric Rheumatology
University of Alabama at Birmingham Heersink School of Medicine
Birmingham, AL
Relevant Financial Disclosure:
Advisor: Sobi
Consultant: Sironax, Sobi
Speaker Contracted by Ineligible Company: Sobi
Independent Research Contractor: Sobi
Adjudication Committee Chair: Pfizer
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Expires: March 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
- Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.
Activity Description
In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.
Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Randy Q. Cron, MD, PhD
Professor of Pediatrics
Arthritis Foundation, Alabama Chapter Endowed Chair in Pediatric Rheumatology
University of Alabama at Birmingham Heersink School of Medicine
Birmingham, AL
Relevant Financial Disclosure:
Advisor: Sobi
Consultant: Sironax, Sobi
Speaker Contracted by Ineligible Company: Sobi
Independent Research Contractor: Sobi
Adjudication Committee Chair: Pfizer
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Words Matter – Terms to Use and Avoid When Talking About Addiction
StartActivity Details
0.75 ANCC Contact hour(s)
0.75 ACPE Contact hour(s) (0.075 CEUs)
0.75 ADA Continuing education credit(s)
Expires: October 17, 2023
Provided By
Target Audience
This activity is intended for physicians, physician assistants, pharmacists, registered nurses, nurse practitioners/other APRNs, and dentists engaged in the care of patients with substance use disorders.
Learning Objectives
After completing this activity, the participant should be better able to:
- Explain the effects of stigmatizing language on patients with addiction.
- Compare common terminology and assess which terms should be used or avoided and why.
- Integrate person-first, non-stigmatizing language into everyday practice.
- Identify terms to use and terms to avoid when speaking to patients about addiction.
Activity Description
This CME/CE activity informs clinicians on how they can show leadership in how language can destigmatize the disease of addiction. It is focused on using person-first language, as well as terms to avoid to reduce stigma and negative bias when discussing addiction.
Course Director
Michelle Corbin, MBA
NIDAMED Coordinator
National Institute on Drug Abuse
Rockville, MD
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose.
The following planners and others have nothing to disclose: Michelle Corbin from the National Institute on Drug Abuse, Melinda Campopiano, Erika Capinguian, Susan Hayashi, and Laura Nolan from JBS International, Inc.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine and the National Institute on Drug
Abuse. Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Physician Continuing Medical Education
Postgraduate Institute for Medicine designates this enduring material for a
maximum of 0.75 AMA PRA Category 1
Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.75 contact hour(s).
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education
activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council
for Pharmacy Education.
(Universal Activity Number – JA4008162-9999-21-2678-H01-P)
Type of Activity: Knowledge
Continuing Dental Education
Postgraduate Institute for Medicine is an ADA CERP Recognized Provider. ADA
CERP is a service of the American Dental Association to assist dental
professionals in identifying quality providers of continuing dental
education. ADA CERP does not approve or endorse individual courses or
instructors, nor does it imply acceptance of the credit hours by boards of
dentistry. Concerns or complaints about a CE provider may be directed to the
provider or to the Commission for Continuing Education Provider Recognition
at ADA.org/CERP.
Postgraduate Institute for Medicine designates this activity for 0.75 continuing education credit(s).
Statement of Commercial Support
There is no commercial funding for this activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Hardware/Software Requirements
Content is accessible regardless of internet browser. However, the Google Chrome browser often performs best.
Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
Contact Information for Questions About the Activity
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.
Activity Details
0.75 ANCC Contact hour(s)
0.75 ACPE Contact hour(s) (0.075 CEUs)
0.75 ADA Continuing education credit(s)
Expires: October 17, 2023
Provided By
Target Audience
This activity is intended for physicians, physician assistants, pharmacists, registered nurses, nurse practitioners/other APRNs, and dentists engaged in the care of patients with substance use disorders.
Learning Objectives
After completing this activity, the participant should be better able to:
- Explain the effects of stigmatizing language on patients with addiction.
- Compare common terminology and assess which terms should be used or avoided and why.
- Integrate person-first, non-stigmatizing language into everyday practice.
- Identify terms to use and terms to avoid when speaking to patients about addiction.
Activity Description
This CME/CE activity informs clinicians on how they can show leadership in how language can destigmatize the disease of addiction. It is focused on using person-first language, as well as terms to avoid to reduce stigma and negative bias when discussing addiction.
Course Director
Michelle Corbin, MBA
NIDAMED Coordinator
National Institute on Drug Abuse
Rockville, MD
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose.
The following planners and others have nothing to disclose: Michelle Corbin from the National Institute on Drug Abuse, Melinda Campopiano, Erika Capinguian, Susan Hayashi, and Laura Nolan from JBS International, Inc.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine and the National Institute on Drug
Abuse. Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Physician Continuing Medical Education
Postgraduate Institute for Medicine designates this enduring material for a
maximum of 0.75 AMA PRA Category 1
Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.75 contact hour(s).
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education
activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council
for Pharmacy Education.
(Universal Activity Number – JA4008162-9999-21-2678-H01-P)
Type of Activity: Knowledge
Continuing Dental Education
Postgraduate Institute for Medicine is an ADA CERP Recognized Provider. ADA
CERP is a service of the American Dental Association to assist dental
professionals in identifying quality providers of continuing dental
education. ADA CERP does not approve or endorse individual courses or
instructors, nor does it imply acceptance of the credit hours by boards of
dentistry. Concerns or complaints about a CE provider may be directed to the
provider or to the Commission for Continuing Education Provider Recognition
at ADA.org/CERP.
Postgraduate Institute for Medicine designates this activity for 0.75 continuing education credit(s).
Statement of Commercial Support
There is no commercial funding for this activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Hardware/Software Requirements
Content is accessible regardless of internet browser. However, the Google Chrome browser often performs best.
Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
Contact Information for Questions About the Activity
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.
Your Words Matter – Language Showing Compassion and Care for Women, Infants, Families, and Communities Impacted by Substance Use Disorder
StartActivity Details
0.75 ANCC Contact hour(s)
0.75 ACPE Contact hour(s) (0.075 CEUs)
0.75 ADA Continuing education credit(s)
Expires: October 17, 2023
Provided By
Target Audience
This activity is intended for physicians, physician assistants, pharmacists, registered nurses, nurse practitioners/other APRNs, and dentists engaged in the care of patients with substance use disorders.
Learning Objectives
After completing this activity, the participant should be better able to:
- Explain the effects of stigmatizing language on patients with addiction.
- Describe the effects of stigma on pregnant women and mothers.
- Compare common terminology and assess which terms should be used or avoided and why.
- Integrate person-first, non-stigmatizing language into everyday practice.
- Identify terms to use and terms to avoid when speaking to patients about addiction.
Activity Description
This CME/CE activity highlights your role in helping destigmatize addiction and substance use disorder and reduce negative bias among pregnant women and mothers. The activity has background information and tips for providers on language to use or avoid.
Course Director
Michelle Corbin, MBA
NIDAMED Coordinator
National Institute on Drug Abuse
Rockville, MD
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose.
The following planners and others have nothing to disclose: Hendree Jones, Michelle Corbin from the National Institute on Drug Abuse, Melinda Campopiano, Erika Capinguian, Susan Hayashi, and Laura Nolan from JBS International, Inc.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine and the National Institute on Drug
Abuse. Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Physician Continuing Medical Education
Postgraduate Institute for Medicine designates this enduring material for a
maximum of 0.75 AMA PRA Category 1
Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.75 contact hour(s).
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education
activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council
for Pharmacy Education.
(Universal Activity Number – JA4008162-9999-21-2679-H01-P)
Type of Activity: Knowledge
Continuing Dental Education
Postgraduate Institute for Medicine is an ADA CERP Recognized Provider. ADA
CERP is a service of the American Dental Association to assist dental
professionals in identifying quality providers of continuing dental
education. ADA CERP does not approve or endorse individual courses or
instructors, nor does it imply acceptance of the credit hours by boards of
dentistry. Concerns or complaints about a CE provider may be directed to the
provider or to the Commission for Continuing Education Provider Recognition
at ADA.org/CERP.
Postgraduate Institute for Medicine designates this activity for 0.75 continuing education credit(s).
Statement of Commercial Support
There is no commercial funding for this activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Hardware/Software Requirements
Content is accessible regardless of internet browser. However, the Google Chrome browser often performs best.
Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
Contact Information for Questions About the Activity
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.
Activity Details
0.75 ANCC Contact hour(s)
0.75 ACPE Contact hour(s) (0.075 CEUs)
0.75 ADA Continuing education credit(s)
Expires: October 17, 2023
Provided By
Target Audience
This activity is intended for physicians, physician assistants, pharmacists, registered nurses, nurse practitioners/other APRNs, and dentists engaged in the care of patients with substance use disorders.
Learning Objectives
After completing this activity, the participant should be better able to:
- Explain the effects of stigmatizing language on patients with addiction.
- Describe the effects of stigma on pregnant women and mothers.
- Compare common terminology and assess which terms should be used or avoided and why.
- Integrate person-first, non-stigmatizing language into everyday practice.
- Identify terms to use and terms to avoid when speaking to patients about addiction.
Activity Description
This CME/CE activity highlights your role in helping destigmatize addiction and substance use disorder and reduce negative bias among pregnant women and mothers. The activity has background information and tips for providers on language to use or avoid.
Course Director
Michelle Corbin, MBA
NIDAMED Coordinator
National Institute on Drug Abuse
Rockville, MD
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose.
The following planners and others have nothing to disclose: Hendree Jones, Michelle Corbin from the National Institute on Drug Abuse, Melinda Campopiano, Erika Capinguian, Susan Hayashi, and Laura Nolan from JBS International, Inc.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine and the National Institute on Drug
Abuse. Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Physician Continuing Medical Education
Postgraduate Institute for Medicine designates this enduring material for a
maximum of 0.75 AMA PRA Category 1
Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.75 contact hour(s).
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education
activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council
for Pharmacy Education.
(Universal Activity Number – JA4008162-9999-21-2679-H01-P)
Type of Activity: Knowledge
Continuing Dental Education
Postgraduate Institute for Medicine is an ADA CERP Recognized Provider. ADA
CERP is a service of the American Dental Association to assist dental
professionals in identifying quality providers of continuing dental
education. ADA CERP does not approve or endorse individual courses or
instructors, nor does it imply acceptance of the credit hours by boards of
dentistry. Concerns or complaints about a CE provider may be directed to the
provider or to the Commission for Continuing Education Provider Recognition
at ADA.org/CERP.
Postgraduate Institute for Medicine designates this activity for 0.75 continuing education credit(s).
Statement of Commercial Support
There is no commercial funding for this activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Hardware/Software Requirements
Content is accessible regardless of internet browser. However, the Google Chrome browser often performs best.
Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
Contact Information for Questions About the Activity
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.